For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-42

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-21

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 20
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-20

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 18
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482861/275-10-50-18

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 20
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482861/275-10-50-20

Name:	us-gaap_ConcentrationRiskPercentage1
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

Revenue Recognition - Nature of Goods and Services (Details) $ in Millions	3 Months Ended			6 Months Ended		12 Months Ended
	Jun. 30, 2024	Dec. 31, 2023 USD ($)	Jun. 30, 2023	Jun. 30, 2024 agreement segment	Jun. 30, 2023	Dec. 31, 2023
Revenue Recognition [Line Items]
Number of operating market segments \| segment				1
Customers average payment term				30 days
Distributors average payment term				60 days
Number of distribution and license agreements \| agreement				5
Da Vita Healthcare Partners Inc
Revenue Recognition [Line Items]
Product purchase agreement, one time payment from counterparty \| $		$ 0.4
Da Vita Healthcare Partners Inc \| Revenue Benchmark \| Customer Concentration Risk
Revenue Recognition [Line Items]
Customer concentration, percentage	45.00%		51.00%	44.00%	50.00%
Da Vita Healthcare Partners Inc \| Accounts Receivable \| Customer Concentration Risk
Revenue Recognition [Line Items]
Customer concentration, percentage				35.00%		35.00%